Daniel Petrylak, MD, Yale School of Medicine, New Haven, CT, discusses the unmet needs of patients with prostate cancer, including an agent that is curative. Current agents are able to prolong survival when used in earlier disease settings, however, there is a lack of iomarkers to help identify which patients benefit to avoid unnecessary associated toxicities. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.